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Abstract 
Primary  pancreatic  small  cell  carcinoma
(SCC) is rare, with just over 30 cases reported
in  the  literature.  Only  7  of  these  patients
underwent surgical resection with a median
survival  of  6  months.  Prognosis  of  SCC  is
therefore considered to be poor, and the role of
adjuvant therapy is uncertain. Here we report
two  institutions’  experience  with  resectable
pancreatic SCC. Six patients with pancreatic
SCC treated at the Johns Hopkins Hospital (4
patients)  and  the  Mayo  Clinic  (2  patients)
were  identified  from  prospectively  collected
pancreatic cancer databases and re-reviewed
by pathology. All six patients underwent a pan-
creaticoduodenectomy. Clinicopathologic data
were analyzed, and the literature on pancreat-
ic SCC was reviewed. Median age at diagnosis
was  50  years  (range  27-60).  All  six  tumors
arose  in  the  head  of  the  pancreas.  Median
tumor size was 3 cm, and all cases had positive
lymph nodes except for one patient who only
had five nodes sampled. There were no periop-
erative deaths and three patients had at least
one  postoperative  complication.  All  six
patients  received  adjuvant  therapy,  five  of
whom  were  given  combined  modality  treat-
ment with radiation, cisplatin, and etoposide.
Median survival was 20 months with a range of
9-173  months.  The  patient  who  lived  for  9
months received chemotherapy only, while the
patient who lived for 173 months was given
chemoradiation  with  cisplatin  and  etoposide
and represents the longest reported survival
time from pancreatic SCC to date. Pancreatic
SCC is an extremely rare form of cancer with a
poor prognosis. Patients in this surgical series
showed  favorable  survival  rates  when  com-
pared  to  prior  reports  of  both  resected  and
unresectable  SCC.  Cisplatin  and  etoposide
appears to be the preferred chemotherapy reg-
imen, although its efficacy remains uncertain,
as does the role of combined modality treat-
ment with radiation.
Introduction
More than 42,000 cases of pancreatic cancer
occur in the United States each year. The most
common  forms  of  pancreatic  cancer  in
descending order of frequency are ductal ade-
nocarcinoma,  intraductal  papillary  mucinous
neoplasms with invasive cancer, and well-dif-
ferentiated neuroendocrine tumors. However,
more than a dozen other rarer types have been
described,
1 many  of  which  are  biologically
aggressive and present at an advanced stage.
As  imaging  technology,  chemotherapy,  and
access  to  health  care  improve,  surgery  will
likely  take  on  a  more  important  role  in  the
management of these rarer pancreatic cancer
subtypes.  Institutional  series,  reviews,  and
meta-analyses of these cancers are necessary
so that surgeons and pathologists can identify
them when encountered and render the appro-
priate diagnosis, prognosis, and treatment.
Small cell carcinoma (SCC) of the pancreas
is an example of a rare pancreatic cancer, with
just over 30 cases described in the literature.
Most of the SCC literature to date focuses on
small cell lung carcinoma (SCLC), which com-
prises 25% of all lung cancers.
2 While 96% of
small cell carcinomas originate in the lung,
2
small cell carcinomas can arise from multiple
sites in the body, including the gastrointestinal
system,  larynx,  pharynx,  paranasal  sinuses,
uterus, cervix, ovaries, bladder, and prostate.
Furthermore periampullary small cell carcino-
mas have been described in the duodenum,
3
bile duct,
4-6 ampulla of Vater,
7 and pancreas.
2
Historically  considered  an  exocrine  tumor,
pancreatic SCC is now classified as a neuroen-
docrine carcinoma that can be distinguished
from  more  common  lower-grade  pancreatic
neuroendocrine tumors by its high mitotic rate
(>20 mitoses per 10 high power fields), infil-
trative pattern of growth, minimal cytoplasm,
finely granular cytoplasm, and nuclear mold-
ing.
2,8We present the experience of two institu-
tions,  the  Johns  Hopkins  Hospital  and  the
Mayo Clinic, with resectable small cell carcino-
ma of the pancreas and provide an updated
review  of  the  literature,  with  a  particular
emphasis on resected pancreatic SCC.
Materials and Methods
This study was approved by the Institutional
Review Boards of the Johns Hopkins Hospital,
Baltimore and the Mayo Clinic, Rochester. At
the  Johns  Hopkins  Hospital,  a  prospectively
collected  pancreaticoduodenectomy  database
and the Department of Pathology patient data-
base were queried for all surgical cases of pan-
creatic  SCC.  Between  1970  and  2007,  of  all
patients undergoing a pancreaticoduodenecto-
my, four patients were identified with pancre-
atic  SCC,  representing  0.3%  of  all  operable
pancreatic cancer cases. At the Mayo Clinic, a
prospectively collected database of all cases of
pancreatic  neoplasms  was  maintained  from
1975 to 2005 through the Mayo Clinic Tumor
Registry and updated through a retrospective
chart review. There were 3,694 patients with
ductal adenocarcinoma during this period, and
64 patients with other rare tumor types. Only
two  patients  with  resected  pancreatic  SCC
were  identified,  representing  0.0005%  of  all
pancreatic  cancer  cases  seen  at  the  Mayo
Clinic. Baseline demographic, clinicopatholog-
ic, treatment, and long-term survival data were
reviewed for each patient.
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Results
There were six patients identified with SCC
of the pancreas. Three of the six patients were
male, and three of the patients were known
smokers. Median age at diagnosis was 50 years
(range 27-60 years). The most common pre-
senting symptoms were abdominal pain (67%)
and jaundice (67%). None of the patients died
perioperatively,  although  three  patients  suf-
fered  postoperative  complications,  including
two  patients  with  wound  infections,  one  of
whom also experienced delayed gastric empty-
ing, and a third patient with an intra-abdomi-
nal abscess requiring percutaneous drainage.
Overall, the median length of hospital stay was
12 days (range 10-23). These data are summa-
rized in Table 1. All six carcinomas originated
in the head of the pancreas. One of the carci-
nomas directly extended into the duodenum,
and another involved the portal vein. Median
tumor diameter was 3 cm (range 3-4.5 cm).
Lymph  node  metastases  were  indentified  in
five patients, while the sixth patient only had
five lymph nodes sampled and therefore may
have been understaged. This patient was also
the  only  one  of  the  series  to  have  positive
resection margins. Three patients had micro-
scopic  vascular  or  perineural  invasion.  The
pathology data are presented in Table 2.
All six patients are deceased. Median sur-
vival was 20 months (range 9-173 months). All
six  patients  received  adjuvant  therapy,
although the precise postoperative regimen is
known only for the single patient treated adju-
vantly at the Johns Hopkins Hospital. As first-
line therapy, this individual received combined
modality  chemoradiation  (50  Gy/2  Gy  frac-
tions) with concurrent cisplatin and etoposide.
This  patient’s  cancer  recurred  in  the  liver
seven months after surgery, and experimental
palliative chemotherapy with a BCL-2 antago-
nist  (obatoclax)  and  topotecan  was  given.
Single-agent paclitaxel was used after the pre-
vious regimen was discontinued due to side
effects, but disease progression continued in
the liver, peritoneal cavity, and lungs. Of the
remaining  five  patients,  four  received  com-
bined modality treatment with cisplatin, etopo-
side,  and  radiation  therapy  at  other  institu-
tions. The remaining patient received neoad-
juvant chemotherapy with 5-fluorouracil, adri-
amycin, and mitomycin, after the cancer was
initially  deemed  locally  unresectable.  While
this patient was found to have positive resec-
tion  margins,  adjuvant  radiation  was  not
given, and it is unknown whether the patient
received further adjuvant chemotherapy.
Discussion
Pancreatic SCC is now widely accepted as a
high  grade  neuroendocrine  carcinoma.
9
Preoperatively, it is difficult to distinguish SCC
from more common types of pancreatic cancers,
because the lesions share similar clinical symp-
toms  and  features  on  imaging  studies.
Resectable pancreatic small cell carcinomas typ-
ically measure about 3 cm. On CT imaging, they
are homogeneous, well-defined, hypoattenuat-
ed  with  minimal  enhancement  after  intra-
venous contrast injection, and may be hypo- or
hyperechoic  on  ultrasound  (Figure  1).
10,11
Macroscopically, lesions appear grey-white in
color and often contain areas of necrosis and
hemorrhage.
2 Microscopically, pancreatic SCC
is indistinguishable from SCLC, consisting of
sheets of discohesive, pleomorphic cells with
scant cytoplasm and high mitotic activity (>20
mitoses per 10 high power fields). Apoptotic
bodies  and  necrotic  foci  are  usually  wide-
spread. The nuclei have hyperchromatic, fine-
ly  granular  chromatin  and  either  absent  or
small nucleoli (Figure 2).
12 Nuclear molding is
often prominent.
Neuroendocrine differentiation is supported
by  the  presence  of  cytoplasmic  membrane-
bound  granules  on  electron  microscopy
although  in  modern  practice  this  workup  is
unnecessary  as  the  neoplastic  cells  are  also
usually reactive to antibodies specific for neu-
roendocrine  differentiation,  such  as  synapto-
physin,  chromogranin  A,  and  CD57.
2,12
Occasionally,  the  neoplastic  cells  react  with
antibodies  to  neurofilaments.
13 Immunohisto  -
chemical labeling for neuron-specific enolase
(NSE) has been used to characterize small cell
Case Report
Table 1. Postoperative data.
Patient Surgery year Complication Length of hospital stay (day)
1 1988 Wound infection 14
2 1989 None NR
3 1991 None NR
4 1996 None 10
5 2007 Abdominal abscess 10
6 2007 Delayed gastric emptying  23
and wound infection
NR, no record.
Table 2. Pathologic data.
Patient Tumor diameter (cm) Node status Local invasion Positive margin Vascular invasion Perineural invasion
13 0/5 Portal vein Yes NR NR
2 NR NR NR No No No
3 NR NR NR No No No
43 13/22 Common bile duct No Yes No
53 10/23 Duodenal wall, bile duct No NR Yes
6 4.5 2/17 None No Yes Yes
NR, no record.
Figure 1. (A) Small cell carcinoma of the pancreas, Gross. (B) Computed tomography
scan, arterial phase.
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carcinomas. Despite its high sensitivity, NSE
lacks specificity as a neuroendocrine marker.
13,14
In the practical work-up of SCC, immunohisto-
chemistry is useful to discern SCC from high
grade lymphoma; SCC labels with antibodies to
high molecular weight cytokeratins but not with
antibodies  to  leukocyte  common  antigen
(CD45). Immunohi  stochemistry has not proven
useful in distinguishing primary peri-ampullary
SCC from metastatic SCLC.
15 Although a high
percentage of lung primaries express thyroid
transcription factor 1 (TTF-1), this marker has
shown variable positivity in patients with extra-
pulmonary  small  cell  carcinoma.
16-19 Further  -
more, the expression of TTF-1 has not been well
explored  in  pancreatic  SCC,  with  only  one
reported negative case in the literature to date.
20
Recent studies have demonstrated that serum
pro-gastrin  releasing  peptide  (ProGRP)  and
serum neuron specific enolase (NSE) levels can
be  elevated  in  patients  with  pancreatic  SCC,
similar to the clinical experience with lung pri-
maries.
21,22 In fact, serum NSE levels were found
to fluctuate with changes in disease burden in a
at least one patient with pancreatic SCC.
22
Due to the rarity of pancreatic SCC, a pul-
monary origin should be presumed in the set-
ting of a suspicious pancreatic mass and a his-
tory of SCLC. Furthermore, any patient with a
pancreatic mass that is suggestive of SCC on
imaging or biopsy should be evaluated with a
chest  CT  to  rule  out  a  lung  primary.
Somatostatin receptor scintigraphy (SRS) may
also have a limited role in the workup of a
patient with a pancreatic mass suggestive of
SCC, although its value above a high quality
CT scan is uncertain. The test has 90% sensi-
tivity for detecting primary SCLC and has also
been described for primary pancreatic SCC.
2,23
In a 2004 comprehensive review of pancre-
atic SCC, Berkel et al. identified 23 cases in
the literature, including one patient from the
authors’  own  experience.  Since  then,  nine
additional cases of pancreatic SCC have been
described,
21,22,24-27 wich are listed in Table 3 in a
format consistent with the summary table pre-
sented in the review by Berkel et al. Missing
data prevented significant analysis for several
of the patients in Berkel’s review, but a recent
publication by Vos et al. examined a subset of
the  aforementioned  32  cases,  focusing  on
patients for which adequate information was
available.  In  this  series  of  23  patients,  the
median age was 62 years (range 37-75 years),
and there was a male predominance (74%).
The median tumor size was 4.2 cm, and the
head of the pancreas was involved in 59% of
cases. At diagnosis, disease was confined to
the  pancreas  in  only  two  cases.  Metastatic
spread to the peripancreatic lymph nodes and
the liver was noted in 62% and 38% of patients,
respectively. Patients receiving either systemic
or local therapy showed a significantly higher
median survival compared to patients treated
with symptomatic management alone (6 vs. 1
month, P≤0.0001). However, the authors found
no  significant  difference  in  median  survival
between  patients  receiving  chemotherapy
alone  and  patients  given  local  treatment  in
addition to chemotherapy, although it should
be noted that the latter group contained only
three  patients.  Overall,  median  survival  was
just 3 months (range 0.5-50 months).
28
The  majority  of  patients  reported  to  date
with pancreatic SCC did not have their tumors
resected.  Table  4  lists  the  seven  previously
reported patients who have had a pancreatic
resection for SCC, along with the six patients
from the present series.
22,24,25,29-32 Three patients
received adjuvant chemotherapy with cisplatin
and  etoposide,  two  received  adjuvant  radia-
tion, and two were treated with surgery alone.
Case Report
Table 3. Recent reported cases of small cell carcinoma of the pancreas.
Age/sex Location Treatment Survival Ref.
41/M Tail Surgery 56 months (25)
58/M Unknown Cis/Et Unknown (27)
62M Head Car/Et 9 months (26)
62/F Head Cis/Et, Surgery 36 months (24)
64F Body Car/Et 56 months (26)
68/M Body Cis/Et 4 months (21)
69/F Head Cis/Et, Surgery 6 months (22)
69M Head Car/Et 14 months (26)
69M Body Car/Et 18 months (26)
RT, external beam radiation; Car, carboplatin; Cis, cisplatin; Et, etoposide; 5FU, 5-fluorouracil.
Table 4. Surgical cases of small cell carcinoma of the pancreas.
Age/sex Location Adjuvant therapy Survival Ref.
37F Head IORT 6 months (29)
40M Tail Cis/Et, Doxorubicin NR (30)
41/M Tail None 56 months (25)
62/F Head Cis/Et 64 months (24)
65F NR RT 1 month (31)
69/F Head Cis/Et 6 months (22)
71M Body None 6 months (32)
Present series
27/M Head RT, Cis/Et, 5FU, Intrathecal methotrexate 73 months
47/F Head RT, Cis/Et 26 months
48/M Head Neoadjuvant 5FU, mitomycin C, adriamycin 9 months
51/M Head RT, Cis/Et 173 months
53/F Head RT, Cis/Et 14 months
60/F Head RT, Cis/Et, Obt/Top, Paclitaxel 13 months
IORT, intraoperative radiation; RT, external beam radiation; Cis, cisplatin; Et,  etoposide; 5FU, 5-fluorouracil; NR, no record.
Figure 2. Small cell carcinoma of the pancreas, Microscopic. At low magnification (100x,
A), the diffuse architecture of the tumor on the left differs from the normal exocrine pan-
creas on the right. Mitotic figures and apoptotic bodies are abundant enough to be rec-
ognizable at this low magnification. Higher power views (400x, B) of the tumor cells
demonstrate the disorganization, pleomorphism, high nuclear to cytoplasmic ratio, and
finely granular cytoplasm. As in lower magnification fields, mitoses and apoptotic figures
abound. [page 16] [Rare Tumors 2011; 3:e5]
No  patient  received  combined  adjuvant
chemotherapy and radiation. The median sur-
vival was 6 months (range 1-56 months) for
these patients. The present series of surgical
patients almost doubles the reported experi-
ence of resected pancreatic SCC. Interestingly,
all of the tumors originated in the head of the
pancreas, supporting the observation that pan-
creatic SCC is more common in the head than
in the body or tail.
33 Five patients in the pres-
ent series received combined modality adju-
vant therapy using cisplatin and etopside, in
conjunction with radiation. To our knowledge,
this represents the first report of tri-modality
therapy for pancreatic SCC.
Surgical management remains the standard
treatment  for  well  differentiated  neuroen-
docrine tumors. However, the benefit of sur-
gery for high grade neuroendocrine carcino-
mas has not been established. Certainly, the
poor survival after surgery reported to date (6
months  median  survival)  might  lead  one  to
question  the  utility  of  pancreatectomy  for
high-grade  neuroendocrine  carcinoma.
However, in the present series, three of six
patients survived more than 2 years, and two
patients survived over five years. The patient
who  lived  for  173  months  represents  the
longest reported survival for pancreatic SCC to
date.    The  median  survival  was  20  months,
which is comparable to patients with resected
ductal  adenocarcinoma  of  the  pancreas.(33-
36) Despite the small patient size in our study,
we believe that combined local and systemic
treatments,  such  as  surgery  and  adjuvant
chemoradiotherapy,  should  be  considered  in
resectable pancreatic small cell carcinoma. 
Conclusions
Pancreatic SCC is an extremely rare form of
pancreatic cancer and occurs primarily in the
head of the pancreas. Although these carcino-
mas  are  associated  with  an  extremely  poor
prognosis, survival beyond a few years is possi-
ble, as was observed in three patients in the
present  surgical  series  and  two  previously
reported cases of resectable disease. The regi-
men  of  cisplatin,  etoposide,  and  radiation  is
generally the favored treatment for pancreatic
SCC.  Surgery  and  adjuvant  chemoradiation
should  be  considered  in  patients  with
resectable small cell carcinoma of the pancreas.
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